NEW YORK (GenomeWeb) – Thermo Fisher Scientific brand One Lambda said today that it has signed an exclusive licensing agreement with Transcriptome Sciences for its transplant rejection testing technology, the Molecular Microscope Diagnostic System (MMDx).
MMDx is a central diagnostic system that uses Thermo Fisher's MyGeneChip custom microarrays to measure transcript levels in biopsy samples, and then apply algorithms that compare those expression results to a set of reference biopsies for diagnosing organ transplant rejection.
University of Alberta physician Phil Halloran developed the system initially for kidney transplants, and the university commercialized the technology through its associated commercial firm, Transcriptome Sciences. MMDx has since been adapted to read heart transplant biopsies and is now also being validated for lung and liver transplant biopsies, the company said.
Additional details on One Lambda's licensing deal were not disclosed.